{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.6","upperLimit":"36.7","value":"26.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from registration to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Use of dasatinib (50 mg orally twice a day) in treatment of pts with previously treated malignant mesothelioma","id":"OG000","title":"Dasatinib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time from registration to death (up to 3 years)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"weeks"}